D-dimer blood test and response to immunotherapy for advanced skin cancer
Part of Heart & circulation clinical trials.
This study looks at whether a blood test called D-dimer can predict how well cemiplimab (an immunotherapy drug) works for advanced skin cancer. If you are already planning to get cemiplimab, the study will collect your D-dimer results and follow your progress to see if the test helps guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of skin cancer called cutaneous squamous cell carcinoma that has spread locally or to other parts of the body.
- Your doctor plans to treat you with cemiplimab (an immunotherapy drug) as part of your standard care.
- You have had a blood test called D-dimer within 7 days before starting cemiplimab.
- You are 18 years old or older.
- You are able to carry out daily activities with little or no help (ECOG score 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a new blood test can predict how well the drug cemiplimab works for skin cancer and if it causes side effects. It may help doctors better match treatments to patients.
This trial tests a drug (cemiplimab) injected directly into early-stage skin cancer (squamous cell carcinoma) to see if it can shrink or cure the cancer before surgery. It may help patients avoid more extensive surgery or reduce the chance of the cancer coming back.
This trial tests a drug called cemiplimab (Libtayo) for kidney transplant recipients who have advanced skin cancer (cutaneous squamous cell carcinoma). The treatment aims to help your immune system fight the cancer while managing your transplant medicines to keep your kidney healthy.
This early-phase study tests cemiplimab (an immune therapy that helps your immune system attack cancer) given before surgery. It aims to shrink tumors and improve outcomes for people with Merkel cell cancer or certain locally advanced skin squamous cell cancers (CSCC).
This Phase 1 study tests a skin-applied treatment called DPCP added to standard PD-1/PD-L1 immunotherapy for cancers that have spread to the skin. It aims to improve control of skin tumors while checking safety and how well the immune system responds.
This study tests different ways of using the drug cemiplimab to treat advanced basal cell skin cancer that cannot be removed with surgery or treated with radiation. It aims to find the most effective approach to shrink or control the cancer.
Hear when a new Cutaneous Squamous Cell Carcinoma (CSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.